Articles By Jack Cush, MD
2016 EULAR Guidelines on RA Management
The management of rheumatoid arthritis (RA) has evolved significantly with time. Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
Patterns of Biologic Use During Autoimmune Pregnancy
While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.
Read Article
IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).
Read ArticleRules for Drug Cessation with Infection
Everyone gets their education about drug-related infection risk from television ads. Rheumatologists should know what the real risks are and educate their patients that they have a higher than normal rate of nonserious infections. But the infection risk is way more related to inflammation than any specific drug risk.
Read Article
Alcohol Related Deaths Increased in Psoriasis
JAMA Dermatology has published a report showing psoriasis carries a 60% greater risk alcohol-related death compared with those without psoriasis. (Citation source: https://buff.ly/2galDwr)
Read Article
Primary Sjögren's Syndrome Guideline from the British Society for Rheumatology
The British Society of Rheumatology (BSR) has been accredited by NICE to develop a guidance document for the management of primary Sjögren's Syndrome intended for rheumatologists, general physicians, general practitioners, specialist nurses and other specialists (e.g.
Read Article
Amgen-Abbvie Settle Humira Biosimilar Patent Dispute
Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.
Read Article
29 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.
Read Article
Psoriasis Increases Risk of Major Adverse Cardiovascular Events
A report in the Journal of the American Academy of Dermatology shows that psoriasis duration and inflammation may result in cardiovascular inflammation and an increased risk of major adverse CV events.
Read Article
